Graduate School and School of Pharmaceutical Sciences, Osaka University

Research

＞

Faculty Members

Regulatory Science for Pharmaceuticals and Medical Devices（Medical and Health Sciences）

Niwa YukiSpecially Appointed Assistant Professor

March 2016: Ph.D. in Science at Keio University
April 2015-March 2018: Research Associate, Department of Applied Chemistry, Faculty of Science and Technology, Keio University
April 2018-January 2019: Postdoctoral Fellow, National Institute of Advanced Industrial Science and Technology
February 2019-March 2024: Researcher, Eisai Co., Ltd.
April 2024-: Current position

Research theme

Drug discovery for cancer targeting epithelial barrier

Because approximately 90% of cancer are derived from epithelial cells, epithelial barrier molecules are considered to be one of the promising targets for cancer. Therefore, I am focusing of the epithelial barrier molecules, especially the claudin family, and studying the possibility of drug discovery for cancer targeting claudins.

Representative achievements

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody.
Yuki Niwa, Keito Adachi, Kimiyo Tabata, Ryoga Ishida, Koichiro Hotta, Tomomi Ishida, Yuji Mano, Yoichi Ozawa, Yukinori Minoshima, Yasuhiro Funahashi, Taro Semba
Mol. Cancer Ther., 22, 499–510, 2023

URL:https://aacrjournals.org/mct/article/22/4/499/719015/Liposome-Encapsulated-Eribulin-Shows-Enhanced

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Yuki Niwa, Makoto Asano, Takayuki Nakagawa, Damien France, Taro Semba, Yasuhiro Funahashi
Anticancer Res., 40, 6699-6712, 2020

URL:https://ar.iiarjournals.org/content/40/12/6699.long

Identification and characterization of collagen-like glycosylation and hydroxylation of CCN1.
Yudai Ishizawa, Yuki Niwa, Takehiro Suzuki, Ryota Kawahara, Naoshi Dohmae, Siro Simizu
Glycobiology, 29, 696-704, 2019

URL:https://academic.oup.com/glycob/article/29/10/696/5533477?login=true

Integrin β1 is an essential factor in vasculogenic mimicry of human cancer cells.
Ryota Kawahara, Yuki Niwa, Siro Simizu
Cancer Sci., 109, 2490-2496, 2018

URL:https://onlinelibrary.wiley.com/doi/10.1111/cas.13693

Regulation of granulocyte colony-stimulating factor receptor-mediated granulocytic differentiation by C-mannosylation.
Kei Otani, Yuki Niwa, Takehiro Suzuki, Natsumi Sato, Yukiko Sasazawa, Naoshi Dohmae, Siro Simizu
Biochem. Biophys. Res. Commun., 498, 466-472, 2018

URL:https://www.sciencedirect.com/science/article/pii/S0006291X18304662?via%3Dihub

Topological analysis of DPY19L3, a human C-mannosyltransferase.
Yuki Niwa, Yoshihiko Nakano, Takehiro Suzuki, Mizuo Yamagishi, Kei Otani, Naoshi Dohmae, Siro Simizu
FEBS J., 285, 1162-1174, 2018

URL:https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.14398

N-glycosylation of R-spondin1 at Asn137 negatively regulates its secretion and Wnt/β-catenin signaling-enhancing activity.
Miyu Tsuchiya, Yuki Niwa, Siro Simizu
Oncol. Lett., 11, 3279-3286, 2016

URL:https://www.spandidos-publications.com/10.3892/ol.2016.4425

Identification of DPY19L3 as the C-mannosyltransferase of R-spondin1 in human cells.
Yuki Niwa, Takehiro Suzuki, Naoshi Dohmae, Siro Simizu
Mol. Biol. Cell, 27, 744-756, 2016

URL:https://www.molbiolcell.org/doi/10.1091/mbc.E15-06-0373?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

O-fucosylation of CCN1 is required for its secretion.
Yuki Niwa, Takehiro Suzuki, Naoshi Dohmae, Siro Simizu
FEBS Lett., 589, 3287-3293, 2015

URL:https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2015.09.012

Determination of cathepsin V activity and intracellular trafficking by N-glycosylation.
Yuki Niwa, Takehiro Suzuki, Naoshi Dohmae, Kazuo Umezawa, Siro Simizu
FEBS Lett., 586, 3601-3607, 2012

URL:https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2012.08.001

研究室WEB SITE researchmap